Hold GILD through August 27 PDUFA; trim 25-30% into strength, defend $132 floor
Hold GILD with 4-5% portfolio weight through the August 27 PDUFA catalyst. The balance sheet deterioration is transitional rather than terminal (underlying FCF engine intact at $3.43B quarterly), but the technical setup is stretched (78% up Bollinger channel, MACD histogram divergence at 1.18 vs. 1.30 peak), the 1:3 risk-reward to resistance is poor, and binary PDUFA decisions warrant trim discipline rather than additions. Execute 25-30% trim into clean post-approval strength; defend $132 hard stop on rejection/delay; re-engage only on confirmed break above $148.50 with volume >8M or pullback to $139-142 with multi-factor confirmation.
| Position | Action |
|---|---|
| Clean post-approval strength (Yeztugo approval without restrictive labeling, price pops 3-5%) | Trim 25-30% of position |
| Approval with label complexity | Tighten trailing stop to $138 |
| Rejection or delay | Let $132 hard stop work; reassess within 48 hours |
| Price below $132 | Hard stop triggered; exit remaining position |
GILD's Q2 GAAP loss obscures a $9.77B TTM FCF cash machine, and the August 27 FDA decision on Yeztugo represents a highly asymmetric catalyst for multiple expansion at a discounted 14.83x forward P/E.
| Indicator | Value | Signal |
|---|---|---|
| 50 SMA | 132.30 | neutral |
| 200 SMA | 132.09 | bullish |
| 10 EMA | 142.03 | bullish |
| MACD | 3.85 | bullish |
| MACD Signal | 2.67 | bullish |
| MACD Histogram | 1.18 | bullish |
| RSI | 67.72 | bullish |
| Bollinger Middle (20 SMA) | 136.91 | neutral |
| Bollinger Upper Band | 148.33 | bearish |
| Bollinger Lower Band | 125.49 | bullish |
| ATR | 3.93 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Pullback to $139-142 with multi-factor confirmation (RSI cooled to 50-55, MACD histogram compressed, ATR declining, price holding 10 EMA from above)
Then: Re-engage with multi-factor confirmation
↩ rebuts: “Bear treats it as merely binary risk rather than asymmetric opportunity”
· concedes: Don't chase blindly at $146.74+ with no plan; Would prefer pullback to 10 EMA at $142 or Bollinger middle at $137 to add risk; Bear's 'don't chase' tactical entry timing argument is sensible for patient capital
Gilead is a classic value trap: the Q2 impairment reveals poor capital allocation discipline, Yeztugo is a true binary event (not asymmetric upside), the "diversification" narrative is mostly preclinical noise, and the stock has massively underperformed for six months while the bull story hasn't materialized.
· concedes: Operating cash flow of $3.57B is genuinely healthy and shows the core HIV franchise still generates cash; Biktarvy maintains market dominance in daily oral HIV treatment; Yeztugo, if approved broadly without restrictive labeling, would be incrementally positive for revenue trajectory; Valuation would expand if the market regains confidence in management's capital allocation and HIV franchise stability; Higher rates scenario could drive safe-haven flows into defensive pharma names, though current data suggests this hasn't materialized for GILD
→ vs conservative: Six-month underperformance of 24 percentage points is a discount opportunity, not a death sentence — beta of 0.34 and cash generation support mean reversion
→ vs conservative: Balance sheet deterioration is misread — $11 billion acquisition is offensive capital deployment, not fragility; $3.43 billion Q2 FCF proves financial firepower
→ vs conservative: Waiting post-catalyst means chasing the stock 10% higher the morning of August 28 if approved — the point of taking risk is harvesting rewards when information isn't reflected in price
→ vs conservative: GAAP loss from $11 billion R&D charges is accounting optics, not economic substance — operating income of $2.54 billion and 10% revenue growth show franchise strength
→ vs neutral: PEG ratio of 2.14 ignores that GILD is a defensive cash machine, not a growth story — FCF yield above 5% and forward P/E of 14.8 make it mispriced, not expensive
→ vs neutral: The Hold recommendation itself should be the aggressive play — maintaining exposure through the catalyst with tactical trim plan captures upside without capitulating to conservative exit pressure
| neutral |
| VWMA | 137.94 | bullish |
Support: 142.03 · 136.91 · 132.3 · 132.09 · 125.49 | Resistance: 148.33 · 147.6 · 155.38
The technical structure is firmly bullish with price +11.1% above the 200 SMA and all major moving averages stacked on the long side, but the current entry at $146.74 is late in the rally leg. Immediate resistance sits at $148.33 (Bollinger upper band) with the 50/200 SMA "apex zone" at ~$132 providing deep structural support below. MACD histogram divergence (peaked 8/19 at +1.30, now +1.18 despite higher prices) and the 78th-percentile Bollinger position suggest caution for new entries, though RSI still has room and the trend-following setup remains intact. Final recommendation: HOLD for existing holders with trailing stops at $142.03; new positions should wait for pullback to $142/$137 or breakout above $148.50.
Market Cap
$181.95B
Forward P/E
14.83
PEG Ratio
2.14
Price/Book
15.39
Price/Book (Tangible)
Negative
Dividend Yield
2.24%
Beta
0.336
52-Week High
$157.29
52-Week Low
$108.46
50-Day Moving Avg
$131.90
200-Day Moving Avg
$133.06
Book Value/Share
$9.53
Revenue TTM
$30.46B
Q2 2026 Revenue
$7,803M
Q2 2026 Operating Income
$2,539M
Q2 2026 GAAP Net Income
($10,496M)
Q2 2026 Diluted EPS
($8.45)
Q1 2026 Net Income
$2,021M
Q1 2026 Diluted EPS
$1.61
Gross Margin
79.6%
Operating Margin
33.7%
EBITDA Margin
47.9%
GAAP Profit Margin
-10.6%
ROA
14.1%
ROE
-20.7%
Total Assets Q2 2026
$49,362M
Cash & ST Investments Q2 2026
$3,179M
Goodwill Q2 2026
$8,314M
Intangibles Q2 2026
$14,033M
Total Debt Q2 2026
$26,246M
Net Debt Q2 2026
$23,067M
Total Equity Q2 2026
$11,828M
Debt/Equity Q2 2026
223.5%
Current Ratio Q2 2026
1.265
TTM Free Cash Flow
$9.77B
Q2 2026 Operating CF
$3,573M
Q2 2026 FCF
$3,433M
Q2 2026 CapEx
-$140M
Q2 2026 Dividends Paid
-$1,029M
Q2 2026 Buybacks
-$355M
Q2 2026 R&D
$1,764M
Q2 2026 SG&A
$1,921M
Q2 2026 Cost of Revenue
$1,579M
Special Income Charges Q2 2026
-$12.93B
Annual Dividend Commitment
~$4.06B
Annual Buyback Run-Rate
~$1.5-2B
FCF Yield
~5.4%
Working Capital Q2 2026
$2.93B
Acquisition Spending Q2 2026
-$11.21B
Strengths
Concerns
Gilead Sciences is a high-quality, cash-generative biopharmaceutical company with defensive characteristics (beta 0.34) trading at a forward P/E of 14.83 with a 5.4% FCF yield. The Q2 2026 earnings report showed a deceptive headline loss of -$10.5B due to a massive $12.93B non-cash impairment charge tied to a ~$11.2B acquisition, while underlying operating results remained solid with 10.2% revenue growth and ~32.5% operating margins. The balance sheet reflects significant acquisition financing with net debt rising to $23.1B and debt/equity at 223.5%, though TTM FCF of $9.77B provides strong coverage for the ~$4B annual dividend commitment (41% payout ratio). The HIV franchise continues to drive cash flow stability, though acquisition integration and high leverage warrant monitoring.
Macro: Markets pricing hawkish Fed hold through year-end (2% cut by Sept 2026, 12% by Dec 2026 per Polymarket); US recession odds low at 8% by end-2026; gold at $4,640.80 (+0.36%), silver up >18% month-over-month indicating geopolitical/sovereign-debt concerns rather than growth fears; biotech sector in confirmed uptrend with active funds generating 13% annualized 5Y returns vs. 5.3% index; defensive healthcare attractive in no-recession regime but high-growth biotech beta may continue outperforming; IBD reports biopharma giants investing richly in AI-driven drug development.